OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.1011 0.00 (0.00 %) (As of 12/9/2018 04:00 PM ET)Previous Close$0.1011Today's Range$0.1010 - $0.105052-Week Range$0.08 - $0.21Volume225,798 shsAverage Volume315,413 shsMarket Capitalization$21.89 millionP/E Ratio-2.53Dividend YieldN/ABeta3.6 ProfileDiscussionChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California. Receive INNV News and Ratings via Email Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:INNV Previous SymbolNASDAQ:INNV CUSIPN/A Webwww.innovuspharma.com Phone858-964-5123 Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.38 Price-To-Earnings Trailing P/E Ratio-2.53 Forward P/E Ratio-2.53 P/E GrowthN/A Sales & Book Value Annual Sales$8.82 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book10.11 Profitability EPS (Most Recent Fiscal Year)($0.04) Net Income$-6,500,000.00 Net Margins-35.23% Return on Equity-517.44% Return on Assets-71.19% Miscellaneous Employees12 Outstanding Shares216,470,000Market Cap$21.89 million OptionableNot Optionable Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions What is Innovus Pharmaceuticals' stock symbol? Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV." How were Innovus Pharmaceuticals' earnings last quarter? Innovus Pharmaceuticals Inc (OTCMKTS:INNV) announced its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.01) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.00. The business earned $7.38 million during the quarter, compared to analysts' expectations of $7.65 million. Innovus Pharmaceuticals had a negative return on equity of 517.44% and a negative net margin of 35.23%. View Innovus Pharmaceuticals' Earnings History. When is Innovus Pharmaceuticals' next earnings date? Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Innovus Pharmaceuticals. Has Innovus Pharmaceuticals been receiving favorable news coverage? News articles about INNV stock have been trending somewhat positive on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innovus Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Innovus Pharmaceuticals' key competitors? Some companies that are related to Innovus Pharmaceuticals include CTI BioPharma (CTIC), Chiasma (CHMA), Teligent (TLGT), Zynerba Pharmaceuticals (ZYNE), Ovid Therapeutics (OVID), Pharmaxis (PXSLY), vTv Therapeutics (VTVT), Entasis Therapeutics (ETTX), Humanigen (HGEN), Checkpoint Therapeutics (CKPT), Provention Bio (PRVB), KemPharm (KMPH), BioXcel Therapeutics (BTAI), Infinity Pharmaceuticals (INFI) and Otonomy (OTIC). Who are Innovus Pharmaceuticals' key executives? Innovus Pharmaceuticals' management team includes the folowing people: Dr. Bassam B. Damaj, Pres, CEO & Director (Age 50)Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 57)Mr. Ryan J. Selhorn CPA, VP & CFO (Age 36)Mr. Robert C. Verfurth, VP of Sales & Marketing How do I buy shares of Innovus Pharmaceuticals? Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Innovus Pharmaceuticals' stock price today? One share of INNV stock can currently be purchased for approximately $0.1011. How big of a company is Innovus Pharmaceuticals? Innovus Pharmaceuticals has a market capitalization of $21.89 million and generates $8.82 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Innovus Pharmaceuticals employs 12 workers across the globe. What is Innovus Pharmaceuticals' official website? The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com. How can I contact Innovus Pharmaceuticals? Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected] MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 98 (Vote Underperform)Total Votes: 161MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2018 by MarketBeat.com StaffFeatured Article: Why do companies issue stock splits?